Drug Profile
Bavdegalutamide - Arvinas
Alternative Names: ARV-110Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Yale University
- Developer Arvinas
- Class Amides; Antineoplastics; Chlorobenzenes; Cyclohexanes; Fluorobenzenes; Isoindoles; Phenyl ethers; Piperazines; Piperidines; Pyridazines; Small molecules
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 01 Mar 2024 Arvinas announces intention to discuss the alignment of phase III trial in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) with the regulatory authorities in the second quarter of 2024
- 14 Nov 2023 Arvinas completes enrolment in its phase I trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in United Kingdom, France (PO) (NCT05177042)
- 20 Oct 2023 Efficacy and adverse events data from a phase I/II ARDENT trial in Prostate cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)